biotech · Fabry Disease (X-linked lysosomal storage disease). · Kidney Transplant Rejection · SGMO
SANGAMO THERAPEUTICS
SANGAMO THERAPEUTICS, INC
SANGAMO THERAPEUTICS clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 7000 Marina Blvd, Brisbane, California 94005, US
- Founded
- 1995
- Employees
- 266
- Programs
- 25
- Drugs
- 14
- Patents
- 192
SANGAMO THERAPEUTICS projects
7 ClinicalTrials.gov programs sponsored by SANGAMO THERAPEUTICS.
SANGAMO THERAPEUTICS has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CERE-110: Adeno-Associated Virus Delivery of NGF
SANGAMO THERAPEUTICS, INC
Alzheimer's Disease
1 trial -
CERE-120: AAV2-NTN
SANGAMO THERAPEUTICS, INC
Parkinson's Disease
1 trial -
SB-728-T
SANGAMO THERAPEUTICS, INC
HIV Infection
1 trial -
SB-728mR-HSPC Infusion 3 days following busulfan conditioning
SANGAMO THERAPEUTICS, INC
HIV
1 trial -
SB-FIX
SANGAMO THERAPEUTICS, INC
Hemophilia B
1 trial -
ZFN modified T cells
SANGAMO THERAPEUTICS, INC
HIV
1 trial -
hVEGF-A
SANGAMO THERAPEUTICS, INC
Diabetic Neuropathy
1 trial
Frequently asked questions
How many clinical projects does SANGAMO THERAPEUTICS have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.